SLC5A2 and diabetes mellitus: With the increasing interest in the non-glycaemic effects of the pharmacological treatments used for diabetes control, several recent clinical trials and translational studies have explored the hepatic effects linked to the use of anti-diabetic drugs such as the analogues of glucagon-like peptide one or the sodium glucose cotransporter-2 (SGLT2) inhibitors (Ranjbar et al., 2019; Cusi, 2020; Kang et al., 2020; Vincent et al., 2020).